Role of PEG35, Mitochondrial ALDH2, and Glutathione in Cold Fatty Liver Graft Preservation: An IGL-2 Approach

The total damage inflicted on the liver before transplantation is associated with several surgical manipulations, such as organ recovery, washout of the graft, cold conservation in organ preservation solutions (UW, Celsior, HTK, IGL-1), and rinsing of the organ before implantation. Polyethylene glycol 35 (PEG35) is the oncotic agent present in the IGL-1 solution, which is an alternative to UW and Celsior solutions in liver clinical transplantation. In a model of cold preservation in rats (4 °C; 24 h), we evaluated the effects induced by PEG35 on detoxifying enzymes and nitric oxide, comparing IGL-1 to IGL-0 (which is the same as IGL-1 without PEG). The benefits were also assessed in a new IGL-2 solution characterized by increased concentrations of PEG35 (from 1 g/L to 5 g/L) and glutathione (from 3 mmol/L to 9 mmol/L) compared to IGL-1. We demonstrated that PEG35 promoted the mitochondrial enzyme ALDH2, and in combination with glutathione, prevented the formation of toxic aldehyde adducts (measured as 4-hydroxynonenal) and oxidized proteins (AOPP). In addition, PEG35 promoted the vasodilator factor nitric oxide, which may improve the microcirculatory disturbances in steatotic grafts during preservation and revascularization. All of these results lead to a reduction in damage inflicted on the fatty liver graft during the cold storage preservation. In this communication, we report on the benefits of IGL-2 in hypothermic static preservation, which has already been proved to confer benefits in hypothermic oxygenated dynamic preservation. Hence, the data reported here reinforce the fact that IGL-2 is a suitable alternative to be used as a unique solution/perfusate when hypothermic static and preservation strategies are used, either separately or combined, easing the logistics and avoiding the mixture of different solutions/perfusates, especially when fatty liver grafts are used. Further research regarding new therapeutic and pharmacological insights is needed to explore the underlying mitochondrial mechanisms exerted by PEG35 in static and dynamic graft preservation strategies for clinical liver transplantation purposes.

[1]  M. Boros,et al.  Mitochondrial Consequences of Organ Preservation Techniques during Liver Transplantation , 2021, International journal of molecular sciences.

[2]  S. Fieuws,et al.  The effect of organ preservation solutions on short‐term outcomes after liver transplantation: a single‐center retrospective study , 2020, Transplant international : official journal of the European Society for Organ Transplantation.

[3]  J. Roselló-Catafau,et al.  HOPE (hypothermic oxygenated perfusion) strategies in the era of dynamic liver graft preservation , 2020, EBioMedicine.

[4]  D. Meierhofer,et al.  Hypothermic oxygenated perfusion protects from mitochondrial injury before liver transplantation , 2020, EBioMedicine.

[5]  E. Folch-Puy,et al.  Polyethylene Glycol 35 as a Perfusate Additive for Mitochondrial and Glycocalyx Protection in HOPE Liver Preservation , 2020, International journal of molecular sciences.

[6]  S. Donnini,et al.  Endothelial Aldehyde Dehydrogenase 2 as a Target to Maintain Vascular Wellness and Function in Ageing , 2020, Biomedicines.

[7]  A. Somov,et al.  Organ Preservation into the 2020s: The Era of Dynamic Intervention , 2019, Transfusion Medicine and Hemotherapy.

[8]  Hailong Wu,et al.  Alda-1 Ameliorates Liver Ischemia-Reperfusion Injury by Activating Aldehyde Dehydrogenase 2 and Enhancing Autophagy in Mice , 2018, Journal of immunology research.

[9]  V. Giorgio,et al.  ALDH2 Activity Reduces Mitochondrial Oxygen Reserve Capacity in Endothelial Cells and Induces Senescence Properties , 2018, Oxidative medicine and cellular longevity.

[10]  J. Roselló-Catafau,et al.  Aldehyde Dehydrogenase 2 (ALDH2) in Rat Fatty Liver Cold Ischemia Injury , 2018, International journal of molecular sciences.

[11]  J. Roselló-Catafau,et al.  Role of aldehyde dehydrogenase 2 in ischemia reperfusion injury: An update , 2018, World journal of gastroenterology.

[12]  Wen‐qi Huang,et al.  Alda-1, an ALDH2 activator, protects against hepatic ischemia/reperfusion injury in rats via inhibition of oxidative stress , 2018, Free radical research.

[13]  J. Roselló-Catafau,et al.  Cytoprotective Mechanisms in Fatty Liver Preservation against Cold Ischemia Injury: A Comparison between IGL-1 and HTK , 2018, International journal of molecular sciences.

[14]  J. Decuypere,et al.  The Crosstalk between ROS and Autophagy in the Field of Transplantation Medicine , 2017, Oxidative medicine and cellular longevity.

[15]  Kedar Ghimire,et al.  Nitric oxide: what's new to NO? , 2017, American journal of physiology. Cell physiology.

[16]  J. Roselló-Catafau,et al.  Polyethylene glycols: An effective strategy for limiting liver ischemia reperfusion injury. , 2016, World journal of gastroenterology.

[17]  P. Bachellier,et al.  Compared Efficacy of Preservation Solutions in Liver Transplantation: A Long‐Term Graft Outcome Study From the European Liver Transplant Registry , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  J. Roselló-Catafau,et al.  Polyethylene glycol rinse solution: an effective way to prevent ischemia-reperfusion injury. , 2014, World journal of gastroenterology.

[19]  H. Ohdan,et al.  Ischemia–reperfusion injury in patients with fatty liver and the clinical impact of steatotic liver on hepatic surgery , 2014, Surgery Today.

[20]  A. Said Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances. , 2013, World journal of gastroenterology.

[21]  S. Donnini,et al.  Mitochondrial aldehyde dehydrogenase-2 activation prevents &bgr;-amyloid-induced endothelial cell dysfunction and restores angiogenesis , 2013, Journal of Cell Science.

[22]  A. Seifalian,et al.  The nitric oxide pathway – evidence and mechanisms for protection against liver ischaemia reperfusion injury , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[23]  K. Vekemans,et al.  Presumed and actual concentrations of reduced glutathione in preservation solutions. , 2011, Transplantation proceedings.

[24]  J. Roselló-Catafau,et al.  How to protect liver graft with nitric oxide. , 2011, World journal of gastroenterology.

[25]  Alexander Y. Petrenko,et al.  Organ Preservation: Current Concepts and New Strategies for the Next Decade , 2011, Transfusion Medicine and Hemotherapy.

[26]  J. Roselló-Catafau,et al.  Pharmacological strategies against cold ischemia reperfusion injury , 2010, Expert opinion on pharmacotherapy.

[27]  D. Segev,et al.  Histidine–Tryptophan–Ketoglutarate (HTK) Is Associated with Reduced Graft Survival in Deceased Donor Livers, Especially Those Donated After Cardiac Death , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  Wentao Gao,et al.  Autophagy in the liver , 2008, Hepatology.

[29]  R. Franco-Gou,et al.  Preservation of steatotic livers in IGL‐1 solution , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[30]  G. Escolar,et al.  Effects of polyethylene glycol and hydroxyethyl starch in University of Wisconsin preservation solution on human red blood cell aggregation and viscosity. , 2006, Transplantation proceedings.

[31]  J. Roselló-Catafau,et al.  The future of fatty livers. , 2004, Journal of hepatology.

[32]  R. Busuttil,et al.  The utility of marginal donors in liver transplantation , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[33]  B. Descamps-Latscha,et al.  AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. , 2003, Kidney international.

[34]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[35]  P. Clavien,et al.  Hypothermic oxygenated perfusion (HOPE) for fatty liver grafts in rats and humans. , 2017, Journal of hepatology.

[36]  Julio C. B. Ferreira,et al.  Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. , 2014, Physiological reviews.

[37]  F. Ramalho,et al.  Hepatic microcirculatory failure. , 2006, Acta cirurgica brasileira.

[38]  P A Clavien,et al.  Fatty Liver in Liver Transplantation and Surgery , 2001, Seminars in liver disease.